This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Jefferies Sticks to Their Buy Rating for Zymeworks (ZYME)
Jefferies analyst maintained a Buy rating on Zymeworks today and set a price target of $43.00.
End of Quarter Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Currently, the analyst consensus on Zymeworks is a Strong Buy with an average price target of $38.86.
Based on Zymeworks’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $2.41 million and a GAAP net loss of $44.16 million. In comparison, last year the company earned a revenue of $27.11 million and had a GAAP net loss of $22.64 million
Read More on ZYME:
Disclaimer & DisclosureReport an Issue
- Zymeworks price target raised to $37 from $34 at Wells Fargo
- Zymeworks Earns Buy Rating as Non-Dilutive Theravance Deal and Long-Duration YUPELRI Cash Flows Drive Price Target Up to $37
- Zymeworks price target raised to $37 from $35 at Citi
- Zymeworks’ TBPH Acquisition Seen as Cash-Flow Accretive, Supports Buy Rating and Unchanged $34 Price Target
- Morning Movers: Comcast surges after announcing spinoff of NBCUniversal
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
